<?xml version="1.0" encoding="UTF-8"?>
<p>Drugs related to lipid metabolism also affect postprandial blood lipids (
 <xref rid="B110" ref-type="bibr">110</xref>). Statins are considered an effective method to prevent and treat CVD because they can significantly reduce the level of TG (
 <xref rid="B11" ref-type="bibr">11</xref>). In obese and diabetic patients, postprandial FMD was improved by statins (
 <xref rid="B111" ref-type="bibr">111</xref>â€“
 <xref rid="B113" ref-type="bibr">113</xref>). Changes in postprandial lipoprotein metabolism after statins have been studied (
 <xref rid="B114" ref-type="bibr">114</xref>), and atorvastatin significantly reduced postprandial TG, TRL apoB48, VLDL, and IDL apoB100 levels in T2D patients with high TG levels (
 <xref rid="B115" ref-type="bibr">115</xref>). However, it is still controversial whether statins can reduce the level of apoB48 in patients with hypertriglyceridemia (
 <xref rid="B110" ref-type="bibr">110</xref>).
</p>
